Literature DB >> 9209651

Bcl-6 protein expression in normal and neoplastic lymphoid tissues.

B Falini1, M Fizzotti, S Pileri, A Liso, L Pasqualucci, L Flenghi.   

Abstract

The human bcl-6 gene, which is rearranged in about 30% of diffuse large B-cell lymphomas (DLCL-B), encodes for a Kruppel-type zinc finger protein of 706 amino acids. In order to investigate the expression of the bcl-6 gene at the protein level, two monoclonal antibodies (PG-B6a and PG-B6p) directed against the human bcl-6 protein were generated by immunizing Balb/c mice with a recombinant protein corresponding to the amino-terminal region (amino acids 3-484) of bcl-6. PG-B6a (a = avian) recognized the most conserved bcl-6 epitope (expressed in many animal species, including avian). PG-B6p (p = paraffin) reacted with an epitope of bcl-6 partially resistant to fixatives and detectable on microwave-heated paraffin sections. At immunocytochemistry, bcl-6 localized in the nucleus with a microgranular or diffuse pattern. Strong nuclear expression of bcl-6 was mainly detected in normal germinal-center B-cells, whereas mantle- and marginal-zone B cells, as well as plasma cells and marrow B-cell precursors, did not express bcl-6. These immunohistological findings strongly suggest that bcl-6 may play a role as a regulator of germinal-center related functions. All MoAbs stained neoplastic cells of follicular lymphomas, DLCL-B, and Burkitt's lymphomas. In DLCL-B, bcl-6 expression was independent of bcl-6 gene rearrangements and did not correlate with expression of other markers or the proliferation index. Among low-grade B-cell lymphomas, immunostaining for bcl-6 proved useful for differentiating proliferation centers in B-CLL (bcl-2+/bcl-6-) from trapped germinal centers in mantle-cell lymphomas (bcl-2-/bcl-6+). Strong nuclear positivity for bcl-6 was consistently detected in tumor (L&H) cells of nodular, lymphocyte-predominant Hodgkin's disease (NLPHD). These results further support the concept that NLPHD is a histogenetically distinct (germinal-center derived) subtype of HD. Notably, the nuclei of reactive CD3+/ CD4+ T cells near to and rosetting around L&H cells in NLPHD were also strongly bcl-6+, but lacked CD40 ligand (CD40L) expression. This staining pattern clearly differed from that of classic HD, whose cellular background was made up of CD3+/CD4+ T cells showing the bcl-6-/CD40L+ phenotype. The above immunohistological findings suggest that (a) bcl-6 may play a role in regulating B-cell differentiation step(s) occurring within germinal centers; (b) deregulated bcl-6 expression caused by rearrangements may contribute to B-lymphomagenesis; (c) bcl-6 is possibly involved in the pathogenesis of NLPHD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9209651

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  7 in total

1.  Bcl-2, Bcl-6, and the International Prognostic Index are prognostic indicators in patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.

Authors:  Akiko Miyagi Maeshima; Hirokazu Taniguchi; Suguru Fukuhara; Noriyuki Morikawa; Wataru Munakata; Dai Maruyama; Sung-Won Kim; Takashi Watanabe; Yukio Kobayashi; Kensei Tobinai; Hitoshi Tsuda
Journal:  Cancer Sci       Date:  2012-08-14       Impact factor: 6.716

2.  A low-grade B-cell lymphoma with prolymphocytic/paraimmunoblastic proliferation and IRF4 rearrangement.

Authors:  Kengo Takeuchi; Seiji Sakata; Reimi Asaka; Naoko Tsuyama; Akito Dobashi; Masaaki Noguchi
Journal:  Haematologica       Date:  2013-01-08       Impact factor: 9.941

3.  Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival.

Authors:  Yasodha Natkunam; Eric D Hsi; Patricia Aoun; Shuchun Zhao; Paul Elson; Brad Pohlman; Hina Naushad; Martin Bast; Ronald Levy; Izidore S Lossos
Journal:  Blood       Date:  2006-09-05       Impact factor: 22.113

4.  Point mutation of 5' noncoding region of BCL-6 gene in primary gastric lymphomas.

Authors:  Da-Liu Min; Xiao-Yan Zhou; Wen-Tao Yang; Hong-Fen Lu; Tai-Ming Zhang; Ai-Hua Zhen; Pei-Zheng Cao; Da-Ren Shi
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

Review 5.  Insights into the biology of primary central nervous system lymphoma.

Authors:  Maciej M Mrugala; James L Rubenstein; Maurilio Ponzoni; Tracy T Batchelor
Journal:  Curr Oncol Rep       Date:  2009-01       Impact factor: 5.075

6.  Burkitt and Burkitt-Like Lymphomas: a Systematic Review.

Authors:  Khalil Saleh; Jean-Marie Michot; Valérie Camara-Clayette; Yegor Vassetsky; Vincent Ribrag
Journal:  Curr Oncol Rep       Date:  2020-03-06       Impact factor: 5.075

7.  Immunophenotype classification and therapeutic outcomes of Chinese primary gastrointestinal diffuse large B-cell lymphoma.

Authors:  Zizhen Zhang; Yanying Shen; Danping Shen; Xingzhi Ni
Journal:  BMC Gastroenterol       Date:  2012-06-25       Impact factor: 3.067

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.